Annovis Bio launches proposed public offering of common stock and warrants

ANVS•2026-11-04

Annovis Bio launched a proposed underwritten public offering of common stock or pre-funded warrants, together with warrants to buy common stock. Net proceeds would fund buntanetap development for Alzheimer's and Parkinson's diseases, working capital and general corporate purposes.

Annovis Bio launches proposed public offering of common stock and warrants

1. Offering details

Related News

MGIC Investment Q3 2026 net income falls 8% to $174.97 million

Green Thumb Q3 revenue beats estimates on retail, CPG growth

CF Industries Q3 sales rise 12%, beat estimates

Freightos answers shareholder questions ahead of annual meeting

Summit Therapeutics reports Q3 loss on higher R&D spending